Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
89.52 EUR | -0.71% | +0.39% | -0.27% |
24/05 | Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi | MT |
24/05 | Novavax awaits FDA decision on whether its next COVID shot can be offered in US | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.27% | 12TCr | |
+38.51% | 73TCr | |
+33.05% | 60TCr | |
-6.23% | 35TCr | |
+18.78% | 33TCr | |
+1.35% | 28TCr | |
+16.00% | 24TCr | |
+8.09% | 20TCr | |
-5.77% | 20TCr | |
+6.19% | 16TCr |
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- Sanofi, GSK Target COVID-19 Vaccine Availability in Late-2022 After New Positive Late-stage Data